Det nye forumet finner du her

Tilbake til: Farma og medisin
Innlegg av: Hyggelige (03.05.18 23:37 ), lest 381 ganger
Ticker: BIOTEC

RE^1: Hva skjer i BIOTEC Pharma etter 1 mai ?

Appropriate use of soluble beta-glucan in the management of slow-healing wounds: round table recommendations


Resource topics: Chronic and complex wounds, Diabetic foot ulcers, Wellbeing and concordance

Date: 1 May 2018

Author(s): Simon Barrett, Jacqui Fletcher, Lynne Hepworth, Duncan Stang, Ros Thomas, Joy Tickle, Donna Welch


Slow-healing, chronic wounds have a negative impact on patient wellbeing, are challenging for clinicians to manage and are costly to the health economy (Frykberg and Banks, 2015). Woulgan is a newly available wound care gel containing the active ingredient 2% soluble beta-glucan. Beta-glucan has immunomodulating properties and has been shown to kick-start the healing of slow-healing wounds. A working group of key opinion leaders met in January 2018 to determine the potential role of Woulgan gel in slow-healing wounds, such as diabetic foot ulcers, pressure ulcers and venous leg ulcers, and to develop a decision pathway for clinical practice to support clinicians in escalating treatment promptly to avoid unnecessary impact on patient wellbeing and costs. The group’s consensus recommendations on appropriate use are presented here.


https://www.wounds-uk.com/journals/issue/468/article-details/appropriate-use-soluble-beta-glucan-management-slow-healing-wounds-round-table-recommendations

https://imma.gr/l/70966x4198a